Dr. Iwase on Elevated Neutrophil to Lymphocyte Ratio to Predict Survival Outcome in TNBC

Video

Toshiaki Iwase, MD, Department of General Surgery, Chiba Graduate School of Medicine, Chiba, Japan, discusses a study that examined elevated neutrophil to lymphocyte ratio to predict survival outcomes after recurrence in patients with triple-negative breast cancer.

Toshiaki Iwase, MD, Department of General Surgery, Chiba Graduate School of Medicine, Chiba, Japan, discusses a study that examined elevated neutrophil to lymphocyte ratio to predict survival outcomes after recurrence in patients with triple-negative breast cancer (TNBC).

Recent studies show that obesity plays a role in causing chronic inflammation and limited research focuses on effects of obesity on recurrent breast cancer treatments. In this study, researchers sought to clarify the impact of obesity-related inflammation by using the neutrophil to lymphocyte ratio in recurrent breast cancer treatment.

Results showed that there was no correlation between obesity and the neutrophil to lymphocyte ratio, Iwase explains. However, it was found that the intrinsic subtype was significantly related to inflammation, leading to pre-sarcopenia and a worse overall survival.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute